Compare Stocks: FGEN, HUMA, ADCT, and ENTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.19 +4.9%	$1.19	$0.78 ▼ $4.98	$150.09M	1.89	814,476 shs	664,250 shs
ENTX Entera Bio	$3.00 -1.3%	$1.92	$0.91 ▼ $4.20	$149.84M	1.37	4.93 million shs	487,928 shs
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
HUMA Humacyte	$0.71 -4.6%	$0.82	$0.55 ▼ $2.55	$165.29M	2.53	4.12 million shs	3.52 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+4.87%	+7.24%	-7.78%	-65.91%	-55.70%
ENTX Entera Bio	-1.32%	+4.53%	+81.27%	+132.56%	+59.57%
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	+16.73%
HUMA Humacyte	-4.63%	-0.31%	+2.35%	-37.17%	-59.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.19 +4.9%	$1.19	$0.78 ▼ $4.98	$150.09M	1.89	814,476 shs	664,250 shs
ENTX Entera Bio	$3.00 -1.3%	$1.92	$0.91 ▼ $4.20	$149.84M	1.37	4.93 million shs	487,928 shs
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
HUMA Humacyte	$0.71 -4.6%	$0.82	$0.55 ▼ $2.55	$165.29M	2.53	4.12 million shs	3.52 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+4.87%	+7.24%	-7.78%	-65.91%	-55.70%
ENTX Entera Bio	-1.32%	+4.53%	+81.27%	+132.56%	+59.57%
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	+16.73%
HUMA Humacyte	-4.63%	-0.31%	+2.35%	-37.17%	-59.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$6.25	427.43% Upside
ENTX Entera Bio	2.00	Hold	$9.00	200.00% Upside
FGEN FibroGen	2.00	Hold	$43.00	340.12% Upside
HUMA Humacyte	2.75	Moderate Buy	$6.25	780.28% Upside

Current Analyst Ratings Breakdown

Latest FGEN, HUMA, ADCT, and ENTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ENTX Entera Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	HUMA Humacyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/17/2026	HUMA Humacyte	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$1.50 ➝ $1.25
6/16/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
6/11/2026	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$3.00 ➝ $4.00
6/8/2026	ADCT ADC Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/8/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
6/4/2026	ADCT ADC Therapeutics	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$5.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	1.85	N/A	N/A	($1.50) per share	-0.79
ENTX Entera Bio	N/A	N/A	N/A	N/A	$0.29 per share	N/A
FGEN FibroGen	$29.62M	1.34	N/A	N/A	($50.89) per share	-0.19
HUMA Humacyte	$2.04M	77.27	N/A	N/A	$0.02 per share	35.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$1.05	N/A	N/A	N/A	-173.02%	N/A	-44.70%	8/13/2026 (Estimated)
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-130.95%	-109.82%	N/A
FGEN FibroGen	-$47.58M	$53.48	0.18	N/A	N/A	2,598.55%	N/A	-26.27%	N/A
HUMA Humacyte	-$40.83M	-$0.57	N/A	N/A	N/A	-4,836.06%	-2,914.18%	-89.45%	8/12/2026 (Estimated)

Latest FGEN, HUMA, ADCT, and ENTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.19	N/A	N/A	N/A	$18.89 million	N/A
8/12/2026	Q2 2026	HUMA Humacyte	-$0.0980	N/A	N/A	N/A	$1.12 million	N/A
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
5/13/2026	Q1 2026	HUMA Humacyte	-$0.10	-$0.09	+$0.01	-$0.09	$1.46 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.09	4.02
ENTX Entera Bio	N/A	7.93	7.93
FGEN FibroGen	N/A	3.71	3.60
HUMA Humacyte	5.46	3.93	3.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ENTX Entera Bio	14.11%
FGEN FibroGen	72.71%
HUMA Humacyte	44.71%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
ENTX Entera Bio	10.57%
FGEN FibroGen	3.07%
HUMA Humacyte	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	127.19 million	120.70 million	Optionable
ENTX Entera Bio	20	49.29 million	44.08 million	Optionable
FGEN FibroGen	570	4.05 million	3.92 million	Optionable
HUMA Humacyte	150	222.02 million	215.14 million	Optionable

FGEN, HUMA, ADCT, and ENTX Headlines

Recent News About These Companies

Humacyte Reports Breakthrough V012 Dialysis Access Results, FDA Accepts CTEV IND, and Second-Quarter 2026 Financial Results

43 minutes ago | quiverquant.comQ

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

1 hour ago | globenewswire.com

Humacyte Q2 2026 earnings preview

August 11 at 1:35 PM | msn.com

Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 11 at 4:13 AM | marketbeat.com

Humacyte (HUMA) Expected to Post Earnings on Wednesday

August 11 at 1:26 AM | americanbankingnews.com

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

August 10 at 1:00 PM | businesswire.com

Humacyte to Report Second Quarter 2026 Financial Results and Host Corporate Update Webcast on August 12

August 7, 2026 | quiverquant.comQ

Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts

August 5, 2026 | zacks.com

Humacyte (HUMA) Expected to Announce Earnings on Monday

August 3, 2026 | marketbeat.com

Humacyte (NASDAQ:HUMA) Upgraded at Wall Street Zen

August 1, 2026 | americanbankingnews.com

Humacyte (NASDAQ:HUMA) Rating Increased to Sell at Wall Street Zen

August 1, 2026 | marketbeat.com

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

July 28, 2026 | zacks.com

BTIG Research Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)

July 28, 2026 | marketbeat.com

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

July 27, 2026 | globenewswire.com

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

July 21, 2026 | zacks.com

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

July 20, 2026 | zacks.com

Humacyte Inc. Wt

July 17, 2026 | marketwatch.com

Humacyte, Inc. (NASDAQ:HUMA) Given Average Recommendation of "Moderate Buy" by Analysts

July 17, 2026 | marketbeat.com

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

July 14, 2026 | zacks.com

Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access

July 14, 2026 | globenewswire.com

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

June 30, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FGEN, HUMA, ADCT, and ENTX Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.18 +0.06 (+4.87%)

Closing price 08/11/2026 03:59 PM Eastern

Extended Trading

$1.25 +0.07 (+5.91%)

As of 08:14 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Entera Bio NASDAQ:ENTX

$3.00 -0.04 (-1.32%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$3.00 +0.00 (+0.17%)

As of 08:12 AM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

FibroGen NASDAQ:FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Humacyte NASDAQ:HUMA

$0.71 -0.03 (-4.63%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$0.63 -0.08 (-11.69%)

As of 08:13 AM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, HUMA, ADCT, and ENTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, HUMA, ADCT, and ENTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, HUMA, ADCT, and ENTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FGEN, HUMA, ADCT, and ENTX Company Descriptions

ADC Therapeutics NYSE:ADCT

Entera Bio NASDAQ:ENTX

FibroGen NASDAQ:FGEN

Humacyte NASDAQ:HUMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, HUMA, ADCT, and ENTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, HUMA, ADCT, and ENTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, HUMA, ADCT, and ENTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FGEN, HUMA, ADCT, and ENTX Company Descriptions

ADC Therapeutics NYSE:ADCT

Entera Bio NASDAQ:ENTX

FibroGen NASDAQ:FGEN

Humacyte NASDAQ:HUMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools